MILAN–(BUSINESS WIRE)–Sorin Group, a global medical company and a leader in the treatment
of cardiovascular diseases, announced CE Mark approval and commercial launch
for a comprehensive new range of pacing, defibrillation and left ventricular
leads. Designed for safety and long term reliability, TILDA pacing leads,
VIGILA defibrillation leads and CELERITY left ventricular lead families1 offer
multiple implant options to accommodate patients needs and physicians
preferences.
While all
families benefit from flexible silicone lead body, steroid eluting tips that
reduce inflammation and iridium fractal coated electrodes with proven
electrical performance2, each lead family presents its own additional features:
- Flexible
from the lead connector to the distal tip, TILDA pacing leads are designed to
give physicians the instant sensation of familiarity at implant along with
predictable outcomes. - VIGILA
defibrillation leads feature a symmetrical lead body and thick outer
insulation. Convex shock coils embedded in silicone insulation are engineered
to minimize tissue in-growth. - Intended
to improve control and handling, CELERITY left ventricular leads have a
flexible co-radial body. The three pre-shaped fixation alternatives are
designed to facilitate access and ensure stability in targeted pacing sites
regardless of patients challenging coronary venous anatomies.
TILDA,
VIGILA and CELERITY leads lasting performance and quality, combined with Sorin
Groups unique algorithms, provide reliable and individualized therapies for
patients2.
“These
leads are great additions to the current Sorin Group portfolios,” said Dr David
Le Froy, Consultant Cardiologist, Hammersmith
Hospital, Imperial College Healthcare
Trust, London, UK. “All aspects of the VIGILA,
TILDA and CELERITY leads are carefully designed to enhance ease of use and
handling without compromising electrical performance and safety1,” he added.
“With these new options, more patients will benefit from Sorins unique
therapies such as SafeR™, PARAD+™ BTO™, and SonR®, some of the most efficient
algorithms on the market today.”
“Instilling
greater clinical confidence by delivering high performance, reliability and
value to our customers is at the core of everything we do,” commented Stefano
Di Lullo, Sorin Group, President of the CRM Business Unit. “This comprehensive
lead portfolio complements our state-of-the-art implantable devices perfectly
and will offer significant clinical benefits to each individual patient.”
About
Sorin Group
Sorin Group (www.sorin.com) is a global, medical device company and a
leader in the treatment of cardiovascular diseases. The Company develops,
manufactures, and markets medical technologies for cardiac surgery and for the
treatment of cardiac rhythm disorders. With 3,700 employees worldwide, Sorin
Group focuses on three major therapeutic areas: cardiopulmonary bypass
(extracorporeal circulation and autotransfusion systems), cardiac rhythm
management, and heart valve repair and replacement. Every year, over one
million patients are treated with Sorin Group devices in more than 80 countries.
For more
information, please visit www.sorin.com
1 All
three families are not available for sales or distribution in the USA
2 Sorin Group, data on file
Posted by
Sean Fenske, Editor-in-Chief, MDT
